Portal de Periódicos da CAPES

Mechanism of Pyrimethamine-Induced Megaloblastosis in Human Bone Marrow

1969; Massachusetts Medical Society; Volume: 280; Issue: 24 Linguagem: Inglês

10.1056/nejm196906122802402

1533-4406

Samuel Waxman, Victor Herbert,

Blood disorders and treatments

Megaloblastosis appeared in a patient receiving pyrimethamine. Pyrimethamine seemed to act as does the folate antagonist methotrexate in short-term in vitro culture of the patient's bone marrow. It produced defective deoxyuridine conversion to thymidylate, a defect that was corrected poorly by oxidized and well by reduced folate. Increased deoxyuridine did not correct the defect induced by pyrimethamine or methotrexate but did correct that produced by 5-fluorouracil. As has been suggested, pyrimethamine acts biochemically in man as an antifolate.